Gradient Denervation Technologies (“Gradient”) is a clinical-stage company developing an innovative, minimally invasive ultrasound-based catheter device for the treatment of pulmonary hypertension. Headquartered in Paris, the company is founded on innovation developed by clinicians at the Stanford University Biodesign Program. Gradient’s novel technology harnesses therapeutic ultrasound to treat the nerves running along specific segments of key blood vessels in the pulmonary vasculature. This procedure, termed “pulmonary artery denervation,” aims to reduce the high pressures that are characteristic of the disease.

Gradient will initially focus on patients with pulmonary hypertension due to left-sided heart disease, which affects several million individuals across the US and Europe. There are currently no targeted treatments available for this disease, which has significant negative impacts on quality and length of life.